IFN-β offered greater protection from VSV-mediated oncolysis in HNSCC cells than IFN-α2a at equivalent bioactivity levels, whereas normal cells were equally protected by both interferon subtypes. This evidence concerns the gene IFNB1 and head and neck squamous cell carcinoma.